

Susan M Reutzel-Edens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7567071/publications.pdf>

Version: 2024-02-01

41
papers

2,618
citations

201674

27
h-index

289244

40
g-index

41
all docs

41
docs citations

41
times ranked

2711
citing authors

#	ARTICLE	IF	CITATIONS
1	The unexpected discovery of the ninth polymorph of tolfenamic acid. <i>CrystEngComm</i> , 2021, 23, 3636-3647.	2.6	25
2	Crystal Morphology Modeling of Solvates and Hydrates of Organic Molecular Crystals: Olanzapine Solvate and Dihydrate. <i>Crystal Growth and Design</i> , 2021, 21, 4871-4877.	3.0	2
3	Absorptive Dissolution Testing: An Improved Approach to Study the Impact of Residual Crystallinity on the Performance of Amorphous Formulations. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 1312-1323.	3.3	15
4	Symmetry in the making. <i>Nature Chemistry</i> , 2020, 12, 887-888.	13.6	2
5	Influence of Drug-Silica Electrostatic Interactions on Drug Release from Mesoporous Silica-Based Oral Delivery Systems. <i>Molecular Pharmaceutics</i> , 2020, 17, 3435-3446.	4.6	19
6	Crystal forms in pharmaceutical applications: olanzapine, a gift to crystal chemistry that keeps on giving. <i>IUCr</i> , 2020, 7, 955-964.	2.2	11
7	Diabat method for polymorph free energies: Extension to molecular crystals. <i>Journal of Chemical Physics</i> , 2020, 153, 244105.	3.0	1
8	A Prolific Solvate Former, Galunisertib, under the Pressure of Crystal Structure Prediction, Produces Ten Diverse Polymorphs. <i>Journal of the American Chemical Society</i> , 2019, 141, 13887-13897.	13.7	109
9	Accuracy and reproducibility in crystal structure prediction: the curious case of ROY. <i>CrystEngComm</i> , 2019, 21, 2080-2088.	2.6	55
10	Inconvenient Truths about Solid Form Landscapes Revealed in the Polymorphs and Hydrates of Gandotinib. <i>Crystal Growth and Design</i> , 2019, 19, 2947-2962.	3.0	32
11	Insight into Amorphous Solid Dispersion Performance by Coupled Dissolution and Membrane Mass Transfer Measurements. <i>Molecular Pharmaceutics</i> , 2019, 16, 448-461.	4.6	33
12	A random forest model for predicting crystal packing of olanzapine solvates. <i>CrystEngComm</i> , 2018, 20, 3947-3950.	2.6	13
13	Crystal structure prediction is changing from basic science to applied technology. <i>Faraday Discussions</i> , 2018, 211, 459-476.	3.2	58
14	Coamorphous Active Pharmaceutical Ingredient-Small Molecule Mixtures: Considerations in the Choice of Coformers for Enhancing Dissolution and Oral Bioavailability. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 5-17.	3.3	60
15	Modeling Olanzapine Solution Growth Morphologies. <i>Crystal Growth and Design</i> , 2018, 18, 905-911.	3.0	32
16	Structure searching methods: general discussion. <i>Faraday Discussions</i> , 2018, 211, 133-180.	3.2	3
17	Crystal structure evaluation: calculating relative stabilities and other criteria: general discussion. <i>Faraday Discussions</i> , 2018, 211, 325-381.	3.2	7
18	Applications of crystal structure prediction for organic molecular structures: general discussion. <i>Faraday Discussions</i> , 2018, 211, 493-539.	3.2	8

#	ARTICLE	IF	CITATIONS
19	Evaluating Competing Intermolecular Interactions through Molecular Electrostatic Potentials and Hydrogen-Bond Propensities. <i>Crystal Growth and Design</i> , 2018, 18, 466-478.	3.0	36
20	Direct Observation of Templated Two-Step Nucleation Mechanism during Olanzapine Hydrate Formation. <i>Crystal Growth and Design</i> , 2017, 17, 6382-6393.	3.0	41
21	Absorptive Dissolution Testing of Supersaturating Systems: Impact of Absorptive Sink Conditions on Solution Phase Behavior and Mass Transport. <i>Molecular Pharmaceutics</i> , 2017, 14, 4052-4063.	4.6	33
22	Unraveling Complexity in the Solid Form Screening of a Pharmaceutical Salt: Why so Many Forms? Why so Few?. <i>Crystal Growth and Design</i> , 2017, 17, 5349-5365.	3.0	33
23	Can computed crystal energy landscapes help understand pharmaceutical solids?. <i>Chemical Communications</i> , 2016, 52, 7065-7077.	4.1	146
24	Supersaturation Potential of Salt, Co-Crystal, and Amorphous Forms of a Model Weak Base. <i>Crystal Growth and Design</i> , 2016, 16, 737-748.	3.0	70
25	The potential of computed crystal energy landscapes to aid solid-form development. <i>Drug Discovery Today</i> , 2016, 21, 912-923.	6.4	91
26	Navigating the Waters of Unconventional Crystalline Hydrates. <i>Molecular Pharmaceutics</i> , 2015, 12, 3069-3088.	4.6	62
27	Facts and fictions about polymorphism. <i>Chemical Society Reviews</i> , 2015, 44, 8619-8635.	38.1	499
28	Assessment of the Amorphous "Solubility" of a Group of Diverse Drugs Using New Experimental and Theoretical Approaches. <i>Molecular Pharmaceutics</i> , 2015, 12, 484-495.	4.6	117
29	A molecular picture of the problems in ensuring structural purity of tazofelone. <i>Journal of Molecular Structure</i> , 2014, 1078, 26-42.	3.6	37
30	Contrasting Polymorphism of Related Small Molecule Drugs Correlated and Guided by the Computed Crystal Energy Landscape. <i>Crystal Growth and Design</i> , 2014, 14, 2056-2072.	3.0	72
31	Exploring the Experimental and Computed Crystal Energy Landscape of Olanzapine. <i>Crystal Growth and Design</i> , 2013, 13, 1602-1617.	3.0	123
32	Development of a Practical Synthesis of an Aminoindanol-Derived M1 Agonist. <i>Organic Process Research and Development</i> , 2009, 13, 198-208.	2.7	16
33	Synthesis, Crystallization, and Biological Evaluation of an Orally Active Prodrug of Gemcitabine. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 6958-6961.	6.4	92
34	Characterization of the "hygroscopic" properties of active pharmaceutical ingredients. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 1047-1059.	3.3	144
35	Diastereomeric Salt Resolution Based Synthesis of LY503430, an AMPA (\pm -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid) Potentiator. <i>Organic Process Research and Development</i> , 2005, 9, 621-628.	2.7	19
36	Crystal forms of LY334370 HCl: Isolation, Solid-State Characterization, and Physicochemical Properties. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 1196-1205.	3.3	32

#	ARTICLE	IF	CITATIONS
37	Anhydrates and Hydrates of Olanzapine: Crystallization, Solid-State Characterization, and Structural Relationships. <i>Crystal Growth and Design</i> , 2003, 3, 897-907.	3.0	125
38	Characterization of the solid state: quantitative issues. <i>Advanced Drug Delivery Reviews</i> , 2001, 48, 67-90.	13.7	168
39	Crystallization and Polymorphism of Conformationally Flexible Molecules: Problems, Patterns, and Strategies. <i>Organic Process Research and Development</i> , 2000, 4, 396-402.	2.7	148
40	Origins of the unusual hygroscopicity observed in LY297802 tartrate. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 1568-1571.	3.3	28
41	Computer-aided solid form design. <i>CrystEngComm</i> , 0, , .	2.6	1